Pfizer's Tukysa Approved by FDA for Front-Line Breast Cancer Treatment
Pfizer (PFE) announced the U.S. Food and Drug Administration (FDA) has approved its drug Tukysa, a tyrosine kinase inhibitor, as part of a combination regimen for front-line maintenance treatment in certain breast cancer patients. The approval expands Tukysa's use to include adults with HER2-positive metastatic or unresectable locally advanced breast cancer. This marks an important milestone for the drug and could increase its adoption among oncologists treating this specific type of breast cancer, potentially boosting Pfizer’s revenue from the product. This regulatory clearance is a significant development in the field of targeted therapies for breast cancer and may influence treatment guidelines as well as market dynamics within the pharmaceutical industry.
Tickers: $PFE